Pharmaceutical Industry
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates - Reuters
House lawmaker brings FDA into biosecurity crackdown on China - FiercePharma
Drugmakers in Medicare negotiations spent more on shareholder payments and marketing than R&D last year: Report - The Hill
The FTC is challenging 'junk' drug patents. Here's what they are and why they matter - Quartz
Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript - The Motley Fool
Readout Newsletter: Regeneron, Eli Lilly, Pfizer updates - STAT
How six trends are driving pharmaceutical milling - Pharmaceutical Technology
The Quest for Greater Channel Visibility in Pharma - Pharmaceutical Executive
Drugs Licensed
No Korea-Originated New Drugs Approved Domestically In 2023 - Pink Sheet
Novel Drug Approvals for 2020 - FDA.gov
Metsera comes out of stealth with $290 million for obesity drugs - STAT
Clinical Trials Underway for Cancer Drugs Licensed by Georgia State University - Georgia State University News
Purdue researchers test previously approved FDA drugs to treat Lowe syndrome - Purdue University
Identification of FDA-approved drugs that induce heart regeneration in mammals - Nature.com
FAQs on Prescription Drug Importation - KFF
Treatments & Medications for MS - National MS Society
Xtandi Approved for High-Risk Prostate Cancer - National Cancer Institute (.gov)
Drugs Patents
The FTC is challenging 'junk' drug patents. Here's what they are and why they matter - Quartz
How sham patents are hurting the pharma industry - Pharmaceutical Technology
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition - ABC News
FTC Warns 'Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How - Forbes
$52.6 Billion: Extra Cost to Consumers of Add-On Drug Patents - UCLA
AHF • AHF Backs FTC Challenge to Big Pharma Junk Patents - AIDS Healthcare Foundation
FTC targets Novo's Ozempic among 300-plus 'junk' patents - FiercePharma
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents - Crowell & Moring LLP
FTC Targets 'Junk' Patent Listings on Ozempic and Other Drugs - The Wall Street Journal
Drugs Generics
A year on, Teva CEO Richard Francis celebrates progress in 'Pivot to Growth' plan - FiercePharma
Office of Generic Drugs 2023 Annual Report - FDA.gov
FDA exploring model master files to expedite generic drug development - Regulatory Focus
Shortages of generic drugs can't be blamed solely on group purchasing organizations - STAT
Competition from 'skinny label' generics saved medicare billions, according to report - Medical Xpress
FTC - HHS.gov
Generic and Biosimilar Medications - National MS Society
California moves to cut medicine prices with novel deal on opioid overdose drugs - Financial Times
Scant drug ingredients linked to US generic-drug shortages in first 2 COVID years - University of Minnesota Twin Cities
FDA Food and Drug Administration
FDA's Final Rule on Laboratory-Developed Tests: Four Key Takeaways - Gibson Dunn
Food safety line item sought to help the FDA with the human food program - Food Safety News
Palmer Candy Company Recalls White Confectionary Products Because of Possible Health Risk - FDA.gov
Counterfeit Version of Botox Found in Multiple States - FDA.gov
FDA increases enforcement efforts for certain imported foods including cheese and seafood - Food Safety News
US FDA advises healthcare facilities to switch from Getinge's heart devices - Reuters
FDA to Host Webinar on the FSMA Final Rule on Pre-Harvest Agricultural - FDA.gov
What does FDA regulate? - FDA.gov
Chairs Rodgers and Guthrie Announce Health Subcommittee Hearing with Key FDA Center Directors - Energy and Commerce Committee
Pharmaceutical Companies
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates - Reuters
House lawmaker brings FDA into biosecurity crackdown on China - FiercePharma
The FTC is challenging 'junk' drug patents. Here's what they are and why they matter - Quartz
Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript - The Motley Fool
Teva Pharmaceutical Industries (NYSE:TEVA) shareholders have earned a 54% return over the last year - Yahoo Finance
Mikart and Nano PharmaSolutions complete key milestones - BioSpace
How sham patents are hurting the pharma industry - Pharmaceutical Technology
Teva Pharmaceutical’s stock climbs as schizophrenia treatment shows promise - MarketWatch
Why Is Teva Pharmaceutical Stock Trading Higher On Wednesday? - Teva Pharmaceutical Indus (NYSE:TEVA) - Benzinga
Retail Pharmacies
Retail pharmacies can engage and empower patients today for a healthier tomorrow - Wolters Kluwer
NACDS applauds enactment of Iowa bill supporting patients' access to essential pharmacist services - Drug Store News
How retail pharmacies can transform clinical trials - EY
Military Pharmacies Restored to Full Operations After Change Healthcare Cyberattack - TRICARE Newsroom
Another drugstore chain files for Chapter 11 bankruptcy - TheStreet
Healthcare Insights: America's Retail Pharmacies - Patients and Pharmacists in Crisis - Cornell University | ILR School
'Pharmacy deserts' spreading across Pennsylvania - Local.News
Selling abortion meds in US drugstores makes them easier to prescribe. Here’s why. - Vox.com
'Pharmageddon' And The Future Of Retail Pharmacies : 1A - NPR
Drug Marketing
Endo Health Solutions ordered to pay $1.5 billion for drug marketing - The Philadelphia Inquirer
Orphan drug market to reach $270B by 2028: Evaluate - FiercePharma
The world's broken market for medicines - Financial Times
Biden-Harris Administration Proposes to Protect People with Medicare Advantage and Prescription Drug Coverage ... - HHS.gov
Luke Greenwalt of IQVIA on Obesity Drug Market | Asembia 2024 - Managed Healthcare Executive
EU Drug Market: Heroin and other opioids — In-depth analysis - European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Global pharmaceutical industry - statistics & facts - Statista
Ransomware hack hits prescription drug market, inconveniencing millions - The Washington Post
Amgen wants in on the booming weight loss drug market — and it's taking a different approach - CNBC